Cardiovascular adverse events (CVAEs) are linked to Carfilzomib (CFZ) therapy in multiple myeloma (MM); however, no validated protocols on cardiovascular risk assessment are available. In this prospective study, the effectiveness of the European Myeloma Network protocol (EMN) in cardiovascular risk assessment was investigated, identifying major predictors of CVAEs. From January 2015 to March 2020, 116 MM patients who had indication for CFZ therapy underwent a baseline evaluation (including blood pressure measurements, echocardiography and arterial stiffness estimation) and were prospectively followed. The median age was 64.53 ± 8.42 years old, 56% male. Five baseline independent predictors of CVAEs were identified: office systolic blood pressure, 24-h blood pressure variability, left ventricular hypertrophy, pulse wave velocity value and global longitudinal strain. The resulting ‘CVAEs risk score’ distinguished a low-and a high-risk group, obtaining a negative predicting value for the high-risk group of 90%. 52 patients (44.9%) experienced one or more CVAEs: 17 (14.7%) had major and 45 (38.7%) had hypertension-related events. In conclusion, CVAEs are frequent and a specific management protocol is crucial. The EMN protocol and the risk score proved to be useful to estimate the baseline risk for CVAEs during CFZ therapy, allowing the identification of higher-risk patients.

Multiple myeloma patients undergoing carfilzomib: Development and validation of a risk score for cardiovascular adverse events prediction

Astarita A.
First
;
Mingrone G.;Airale L.;Vallelonga F.;Covella M.;Cesareo M.;Bruno G.;Leone D.;Cetani G.;Salvini M.;Gay F.;Bringhen S.;Veglio F.;Milan A.
Last
2021-01-01

Abstract

Cardiovascular adverse events (CVAEs) are linked to Carfilzomib (CFZ) therapy in multiple myeloma (MM); however, no validated protocols on cardiovascular risk assessment are available. In this prospective study, the effectiveness of the European Myeloma Network protocol (EMN) in cardiovascular risk assessment was investigated, identifying major predictors of CVAEs. From January 2015 to March 2020, 116 MM patients who had indication for CFZ therapy underwent a baseline evaluation (including blood pressure measurements, echocardiography and arterial stiffness estimation) and were prospectively followed. The median age was 64.53 ± 8.42 years old, 56% male. Five baseline independent predictors of CVAEs were identified: office systolic blood pressure, 24-h blood pressure variability, left ventricular hypertrophy, pulse wave velocity value and global longitudinal strain. The resulting ‘CVAEs risk score’ distinguished a low-and a high-risk group, obtaining a negative predicting value for the high-risk group of 90%. 52 patients (44.9%) experienced one or more CVAEs: 17 (14.7%) had major and 45 (38.7%) had hypertension-related events. In conclusion, CVAEs are frequent and a specific management protocol is crucial. The EMN protocol and the risk score proved to be useful to estimate the baseline risk for CVAEs during CFZ therapy, allowing the identification of higher-risk patients.
13
7
1631
N/A
https://www.mdpi.com/2072-6694/13/7/1631
https://doi.org/10.3390/cancers13071631
Arterial hypertension; Cardiovascular adverse events; Cardiovascular risk assessment; Carfilzomib; Echocardiography; Global longitudinal strain; Multiple myeloma; Pulse wave velocity
Astarita A.; Mingrone G.; Airale L.; Vallelonga F.; Covella M.; Catarinella C.; Cesareo M.; Bruno G.; Leone D.; Giordana C.; Cetani G.; Salvini M.; Gay F.; Bringhen S.; Rabbia F.; Veglio F.; Milan A.
File in questo prodotto:
File Dimensione Formato  
[PUBLISHED Vsn.] Astarita et al - 2021 - Cancers - cancers-13-01631.pdf

Accesso aperto

Descrizione: [PUBLISHED Vsn.] §Astarita et al. Cancers (Basel) . 2021 Apr 1;13(7):1631. doi: 10.3390/cancers13071631.
Tipo di file: PDF EDITORIALE
Dimensione 1.73 MB
Formato Adobe PDF
1.73 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1791009
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact